Applied Molecular Transport announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of MTS Health Partners as advisors in a process to explore strategic alternatives for the company. As part of the restructuring, Tahir Mahmood will leave his post as chief executive officer, but will remain as a board member. Shawn Cross, president and chief operating officer, will now serve as chief executive officer and has been appointed to the board where he will serve as chair. As of February 28, the company had cash and cash equivalents of approximately $47.4M and estimates cumulative severance costs associated with the workforce reductions implemented in March of approximately $4.8M.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMTI:
- Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic Alternatives
- Applied Molecular Transport reports Q4 EPS (58c), consensus (59c)
- Applied Molecular Transport presents additional data from FILLMORE trial
- Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress
- Applied Molecular Transport downgraded to Underperform from Hold at Jefferies
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue